CORMEDIX INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.11 USD | -5.55% |
|
-12.41% | +36.04% |
| May. 09 | Transcript : CorMedix Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 25.16M | Sales 2025 * | 81.93M | Capitalization | 297M |
|---|---|---|---|---|---|
| Net income 2024 * | -45M | Net income 2025 * | 6M | EV / Sales 2024 * | 15 x |
| Net Debt 2024 * | 78.97M | Net Debt 2025 * | 67.68M | EV / Sales 2025 * | 4.46 x |
| P/E ratio 2024 * |
-7.34
x | P/E ratio 2025 * |
-55.5
x | Employees | 83 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on CorMedix Inc.
More recommendations
More press releases
| 1 day | -5.17% | ||
| 1 week | +0.74% | ||
| Current month | +2.95% | ||
| 1 month | +13.89% | ||
| 3 months | +70.13% | ||
| 6 months | +79.14% | ||
| Current year | +43.88% |
1 week
5.36
6.08
1 month
5.007.00
Current year
2.897.00
1 year
2.577.00
3 years
2.578.38
5 years
2.1618.80
10 years
0.8652.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 48 | 22-03-17 |
Mathew David
DFI | Director of Finance/CFO | 47 | 20-05-10 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Myron Kaplan
CHM | Chairman | 79 | 16-04-26 |
Steven Lefkowitz
DFI | Director of Finance/CFO | 68 | 11-08-14 |
Alan Dunton
BRD | Director/Board Member | 70 | 19-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.48% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 5.11 | -5.55% | 815 801 |
| 24-05-09 | 5.41 | -5.17% | 896,049 |
| 24-05-08 | 5.705 | -2.31% | 810,912 |
| 24-05-07 | 5.84 | -0.85% | 466,594 |
| 24-05-06 | 5.89 | +0.86% | 748,677 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.41
USD
Average target price
13
USD
Spread / Average Target
+140.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.88% | 297M | |
| +8.12% | 72.94B | |
| -10.56% | 5.07B | |
| +58.79% | 4.78B | |
| +4.07% | 3.9B | |
| -16.90% | 2.56B | |
| +21.35% | 2.42B | |
| -26.13% | 2.39B | |
| +19.31% | 2.18B | |
| +3.66% | 1.65B |
- Stock Market
- Equities
- CRMD Stock
